Inspire Pharmaceuticals is launching a Phase III clinical trial of a proposed nasal spray for treatment of allergies.

The trial will evaluate epinastine, which targets allergic rhinitis. It is designed to determine the efficacy of the spray to affect runny nose, itchy nose and sneezing as well as other symptoms.

Inspire (Nasdaq: ISPH) expects to report results in the second quarter of 2008.

“We believe that epinastine has the potential to offer patients an alternative to intranasal steroids for the treatment of allergic rhinitis,” said Inspire Chief Executive Officer Christy Shaffer.

Inspire licensed rights to the drug from Boehringer Ingelheim International GmbH in 2006.